ArticleJAMIA open2026
Follow the data: tracking data quality and completeness in oncology real-world data.
Article in JAMIA open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Electronic Health Record (EHR) data are increasingly used in cancer research, yet the fidelity of this data when exchanged between systems remains poorly quantified. This study investigated the agreement in essential biomarker data after they are passed from the EHR into the cancer registry and Fast Healthcare Interoperability Resources (FHIR) extracts. Materials and Methods: This single-institution retrospective study compared demographics and 6 biomarkers from 30 lung cancer patients seen between July 2020 and July 2022. Manual review from the EHR served as the gold standard, with concordance tested between the source EHR, Institutional Cancer Registry, and FHIR exports. Results: Demographics showed high concordance across databases. In contrast, biomarker data present in the source EHR were missing in 80%-100% of FHIR extracts. The demographic registry variables were highly concordant. Discussion: This study reports a significant loss in biomarker data availability across real-world data (RWD) sources. Results underscore critical gaps in RWD extraction or exchange methods and highlight risks of relying on RWD without validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.